BioWorld
  • BioWorld Home
  • About Us
  • Contact BioWorld

BioWorld

Just another weblog
  • Blog Home
  • Editorial Staff
  • Editor’s Picks
  • Contact Us
  • Log In

Medical Progress Is Real

November 6, 2011 – 12:08 pm | By Anette Breindl | No comments yet

recovery

SAN FRANCISCO ‑ I’m enough of a geek that I actually enjoy the details, devil and all, and so I love covering scientific conferences. At the same time, they can be daunting. So much scientific progress is incremental. A case…

Share

Read more
Posted in Big pharma, Biotechnology, Clinical Trial, New Drug Application | Tagged AASLD, AZT, HIV, San Francisco

World’s Oldest Clinical Trial . . . and Health Economics Not Far Behind

November 4, 2011 – 11:18 am | By Trista Morrison | No comments yet

How old is our clinical trial system?

Share

Read more
Posted in Biotechnology, Clinical Trial, Drug Approval, Pharmaceutical, Phase I, Phase II, Phase III | Tagged British Medical Journal, British Navy, Greg Simon, James Lind

Welcome to BioWorld.com 14.0

November 2, 2011 – 11:09 am | By Lynn Yoffee | No comments yet

works

Raise your hand if you remember receiving BioWorld Today via that curly fax paper. Seems like ages ago, right? We used a “fax blaster” in those early days – more than 20 years ago – to deliver your daily dose…

Share

Read more
Posted in Biotechnology, Pharmaceutical |

Reason Free from Passion? That’s Not Biotech

October 27, 2011 – 9:24 am | By Jennifer Boggs | No comments yet

passion

SAN FRANCISCO ‑ At this week’s BIO Investor Forum in San Francisco, there was talk of how the biotech industry has squandered money, paying for infrastructure when it should have been paying only for development and continuing to fund programs…

Share

Read more
Posted in Biotechnology, Drug Approval, Pharmaceutical | Tagged BIO, John Craighead, San Francisco

Pfizer’s Greg Simon Talks Change Blindness in Drug Development

October 20, 2011 – 12:04 pm | By Trista Morrison | No comments yet

230914_eyes_dont_lies_2

If you walked up to a desk to sign a consent form for an experiment, and the person behind the desk bent down to file your form, and a different person stood up – someone with a clearly different face,…

Share

Read more
Posted in Biotechnology, Drug Approval | Tagged Pfizer Inc

Sequencing & Privacy Concerns: Is the Cuckold the Elephant in the Room?

October 14, 2011 – 11:39 am | By Anette Breindl | No comments yet

helix

MONTREAL ‑ At this week’s American Society for Human Genetics annual meeting, where there is a whole genome sequence there is somebody bringing up privacy concerns. Do you really want your genome data to be laid bare? Will it start…

Share

Read more
Posted in Biotechnology, Genomics, Personalized medicine | Tagged Craig Venter, Nobelist James Watson

What’s in a Biotech Name? It’s Greek to Me

October 13, 2011 – 2:13 pm | By Jennifer Boggs | 1 comment

zeus

OK, you’re a biotech entrepreneur and you’ve found some interesting new technology. You’ve secured some seed funding, found some lab space and filled out all the appropriate paperwork for a business license. All’s that left to incorporate your brand new…

Share

Read more
Posted in Biotechnology | Tagged Biotech Name, CEO, Euthymics Bioscience Inc, Ikaria Inc

Biotech Fundraising Plummets in Q3, but Will it Turn on a Dime?

October 10, 2011 – 9:42 am | By Trista Morrison | 1 comment

ball

Biotech companies raised just $2.8 billion in the third quarter of 2011, according to an analysis published in Monday’s BioWorld Insight. That’s a 60 percent drop from the second quarter of this year, and – just in case you thought…

Share

Read more
Posted in Biotechnology, Financing | Tagged Geller Biopharm, Matthew Geller, Pro Bono Bio, Shiv Kapoor

Drug Shortages? We Ain’t Seen Nothin’ Yet

October 6, 2011 – 11:18 am | By Mari Serebrov | No comments yet

bto

You think the drug shortage is a devil now

Share

Read more
Posted in Biosimilar, FDA | Tagged Bachman Turner Overdrive

Ralph Steinman Remembered: A Glimpse of Humility

October 3, 2011 – 11:10 am | By Anette Breindl | No comments yet

ralph

It seems likely that this year’s Nobel Prize for physiology or medicine will be remembered by many people who normally forget about it before the physics prize is even announced. One of the three prize winners, Ralph Steinman, passed away…

Share

Read more
Posted in Biotechnology, immunotherapy | Tagged Associated Press, Nobel Prize, Nobel Prizes, Ralph Steinman
« Previous 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15 Next »

About this Blog

BioWorld Perspectives is the official blog for news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs.

Join the Conversation

 Facebook Twitter LinkedIn YouTube RSS

Subscribe to our Blog

Recent Posts

  • Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally
  • Where’s Superman When He’s Needed?
  • Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs
  • Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985
  • ‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’

Categories

  • Accelerated approval (2)
  • acquisition (1)
  • acute kidney injury (1)
  • aging (1)
  • AIDS (1)
  • antibiotics (2)
  • Antibody (2)
  • Autism (1)
  • Big pharma (28)
  • bioethics (4)
  • Biologic (8)
  • Biosimilar (10)
  • Biotech conferences (9)
  • Biotechnology (95)
  • Biotechnology Industry Organization (8)
  • BLA (3)
  • Cancer (16)
  • Cardiovascular (2)
  • China (4)
  • chronic fatigue syndrome (3)
  • Clinic (4)
  • Clinical Trial (14)
  • Collaboration (5)
  • Complete Response Letter (4)
  • Congress (2)
  • Deals (6)
  • Diabetes (1)
  • DNA (2)
  • Drug Approval (13)
  • drug importation (1)
  • embryonic stem cell research (1)
  • emerging markets (2)
  • epilepsy (1)
  • ethics (1)
  • European Medicines Agency (5)
  • evolution (1)
  • executive salaries (1)
  • FDA (23)
  • Financing (24)
  • FOB (1)
  • Follow-on biologic (2)
  • FTC (1)
  • Gene Therapy (5)
  • generic (2)
  • genetics (4)
  • Genomics (7)
  • Healthcare reform (4)
  • HIV (1)
  • immunotherapy (4)
  • IND (2)
  • Investigational New Drug Application (3)
  • IPO (4)
  • License (2)
  • M&A (6)
  • multidrug resistance (1)
  • mutation (1)
  • National Institutes of Health (1)
  • NDA (3)
  • neurology (3)
  • neuroprostheses (1)
  • neuroprosthetic (1)
  • New Drug Application (7)
  • Obesity (1)
  • OIG (1)
  • Orphan disease (7)
  • pandemic (1)
  • partnering (1)
  • patent cliff (2)
  • Patents (4)
  • PDUFA (4)
  • Personalized medicine (4)
  • Pharmaceutical (21)
  • Phase I (5)
  • Phase II (4)
  • Phase III (6)
  • Pipeline (6)
  • Preclinical (2)
  • prostate cancer (1)
  • Rare disease (3)
  • Reimbursement (9)
  • REMS (1)
  • RNAi (2)
  • SEC (1)
  • sequestration (1)
  • Series A (1)
  • Shareholder value (1)
  • siRNA (2)
  • Stem cell (2)
  • Supplemental new drug application (2)
  • TB (1)
  • traumatic brain injury (1)
  • Tuberculosis (2)
  • Type 2 Diabetes (1)
  • Uncategorized (14)
  • Vaccine (4)
  • venture captial (7)
  • Video (5)
  • virus (2)

Tags

ABH ASCO BIO Biotechnology Industry Organization bioworld BRIC Celgene Corp CEO CFS China Clovis Oncology Inc Cynthia Robbins Roth Day Four Day Three Day Two Dendreon Corp DNA EST EU FDA HCV Hemispherx Biopharma Inc HIV IPO Janssen Labs Mari Serebrov MBA Morgan Healthcare Conference New York New York Times NIH Nobel Prize PDUFA Pfizer Inc PR RNA Roche ROI San Diego San Francisco Seattle Genetics Inc SEC UK VC Vivus Inc

Recommended Blogs

  • Inside Bio
  • Patently Biotech
  • The Catalyst

Recommended Organizations

  • American Society of Clinical Oncology
  • American Society of Hematology
  • BayBio
  • BioIndustry Association
  • Biotechnology Industry Organization

Twitter Updates

    Part of Thompson Media Group LLC: Thompson.com | Sheshunoff.com | ASPratt.com | BioWorld.com | CMEweb.com | Performanceweb.org | ASMIweb.com
    © Copyright 2013 | BioWorld